5 results
A complete list of objectives is presented in Section 2.1 Objectives of the Study Protocol. In summary, the primary objective of this study is to demonstrate a superior LDL-C lowering effect of PF 04950615 150 mg administered by the SC route Q2wks…
1. To evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period
To compare PFS of subjects with newly-diagnosed MGMT methylated or indeterminate GBM subtypes treated with RT plus TMZ combined with nivolumab or placebo. PFS will be determined by BICR based on RANO criteria.To compare OS of subjects with newly-…
A complete list of the study objectives is presented in the Objectives section of the protocol. In summary, the primary objective of this study is to demonstrate a superior LDL-C lowering effect of PF-04950615 150 mg administered by the SC route…
Primary Objective:To evaluate the effect of INS1007 compared with placebo on time to first pulmonary exacerbation over the 24-week treatment period.Secondary Objectives:1. To evaluate the effect of INS1007 compared with placebo on quality of life (…